OGC
MRNA icon

One68 Global Capital’s Moderna MRNA Stock Holding History

One68 Global Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$522K Buy
+5,000
New +$506K 1.05% 23

Other funds holding MRNA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

One68 Global Capital's MRNA Position: Q4 2020 in Review

One68 Global Capital opened a new position in Moderna (MRNA) in Q4 2020: 5,000 shares worth $522K. The stake represents 1.05% of the portfolio and ranks #23 among its holdings.

717 funds tracked by Wall St. Rank hold MRNA as of Q4 2020.

  • One68 Global Capital held 5,000 shares of Moderna worth $522K as of Q4 2020.
  • Moderna was a new One68 Global Capital position in Q4 2020.
  • Moderna made up 1.05% of One68 Global Capital's portfolio in Q4 2020, its #23 holding.
  • 717 funds tracked by Wall St. Rank held Moderna as of Q4 2020.

Based on One68 Global Capital's 13F filing for Q4 2020, filed 16 Feb 2021.